Neoplasm MetastasisNCT00718055
Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients
An observational study of Neoplasm Metastasis and Liver, run by Copenhagen University Hospital at Herlev at 1 site in Denmark.
Trial summary
The purpose of this study is to determine whether MRI with manganese containing contrast agent detects more livermetastasis compared to CT scan Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neoplasm Metastasis, Liver, Colorectal Neoplasms
- How many people
- 50 participants
- Where
- 1 siteDenmark
- Study dates
- Nov 2006to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: consekutive group of liver metastatic patients
Who may be able to join
- biopsy proved liver metastasis
Who cannot join
- pacemaker, metal in the body, claustrophobia, pregnancy, age below 18 years, psychiatry patients
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Copenhagen Uni. Hospital at Herlev dept. of Radiology
Herlev, 2730
About this study
Official title: MR Skanning Med Leverspecifikt Oralt Kontraststof Sammenlignet Med CT Skanning Hos Colorectalcancer Patienter Med Levermetastaser
The purpose of this study is to determine whether MRI with manganese containing contrast agent detects more livermetastasis compared to CT scan
- Conditions
- Neoplasm Metastasis, Liver, Colorectal Neoplasms, Magnetic Resonance Imaging, Contrast Media
- Keywords
- MRI, liverspecific, contrast, colorectal, metastases
- Medical subject headings
- Neoplasm Metastasis, Colorectal Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2008 (estimated)
- Study startNov 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neoplasm MetastasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital at Herlev
- Sponsor type
- University, hospital or other
- Investigators
- Vibeke Løgager, M.D., Principal investigator, Copenhagen University Hospital at Herlev
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00718055
- Sponsor's protocol ID
- KA-20060096
- Status last verified
- Feb 2009
- First submitted
- 4 Oct 2006
- Last updated
- 10 Feb 2009
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MR Skanning Med Leverspecifikt Oralt Kontraststof Sammenlignet Med CT Skanning Hos Colorectalcancer Patienter Med Levermetastaser
- ClinicalTrials.gov ID
- NCT00718055
- Acronym / sponsor ID
- KA-20060096
- Conditions
- Neoplasm Metastasis, Liver, Colorectal Neoplasms, Magnetic Resonance Imaging, Contrast Media
- Keywords
- MRI, liverspecific, contrast, colorectal, metastases
- Study type
- Observational
- Recruitment status
- Withdrawn
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital at HerlevUniversity, hospital or other
- Study start
- Nov 2006
- First posted
- 18 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether MRI with manganese containing contrast agent detects more livermetastasis compared to CT scan
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- consekutive group of liver metastatic patients
Key inclusion criteria (1 listed)
- biopsy proved liver metastasis
Key exclusion criteria (1 listed)
- pacemaker, metal in the body, claustrophobia, pregnancy, age below 18 years, psychiatry patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2009.
Related trials for Neoplasm Metastasis
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingObservational study
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Secondary Malignancies of T-cell Origin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vibeke Løgager, M.D. principal investigator
Copenhagen University Hospital at Herlev
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasm Metastasis and Liver, run by Copenhagen University Hospital at Herlev at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 10 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2009.